Lupus News

Tacrolimus appears to have “synergistic” interactions with mycophenolate mofetil and cyclophosphamide for the treatment of renal involvement in systemic lupus erythematosus, according to observational data published in BMC Rheumatology.

Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to a survey conducted by Spherix Global Insights.

After first generating excitement in late 2022, this year was a bonanza for news about chimeric antigen receptor T-cell therapies for autoimmune rheumatic diseases.

WASHINGTON — A drug combining elsubrutinib with upadacitinib led to lower disease activity for up to 104 weeks in patients with moderately to severely active systemic lupus erythematosus, according to data presented at ACR Convergence 2024.

WASHINGTON — Patients with lupus and type 2 diabetes who receive glucagon-like peptide-1 receptor agonists demonstrate a lower risk for cardiac events and kidney disease progression vs. dipeptidyl peptidase 4 inhibitors, according to data.

The field of rheumatology has “left behind” patients with lupus from Africa — and across the global African diaspora — at nearly all academic and clinical levels, from research to diagnosis to treatment, according to researchers.

WASHINGTON — A phase 1/2 study of CD19 chimeric antigen receptor T-cell therapy in lupus and other autoimmune diseases demonstrated significant response with minimal toxicities, according to data presented at ACR Convergence 2024.

WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over a period of up to 15 months in 35 patients with lupus, myositis and systemic sclerosis, according to data.

WASHINGTON — Patients who use medication or surgery to achieve at least 5% weight loss demonstrate greater improvements in patient-reported outcomes across various rheumatic diseases, according to data presented at ACR Convergence 2024.